Libtayo expansion

Discussion in 'Regeneron' started by anonymous, Nov 21, 2019 at 11:49 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This job is a joke and the management sucks. If you get less than 165k you are a terrible negotiator. Dead end job pursue other jobs
     

  2. anonymous

    anonymous Guest

    The MICROmanagement sucks soooo bad. These managers are tools and no one can stand them. The biggest sucks ups hate them the most and they fall for it. It's painful to watch for the rest of us. Survey results were terrible from our national sales meeting and they still can't understand or wrap their heads around it. Well, when you treat seasoned reps like rookies and children what do you think the outcome will be? More reps will leave, 10 of the original 30 have left. Many just haven't gotten the offer they were going for or the right opportunity has presented yet, but when it does they are out the door. This is not an oncology company. They don't know what they are doing. Keytruda will shut us down, basal cell will not help us one bit as it is too minuscule and nothing in the near future.
     
  3. anonymous

    anonymous Guest

    Dead product walking. Sanofi and Regeneron too delusional to own it. Cut bait and buy another oncology company/drug.
     
  4. anonymous

    anonymous Guest

    Wow given the median age of patients with advanced CSCC, you guys be selling none right now and for the next several weeks.

    feel bad for those patients who cannot come in for treatment due to their advanced age.
     
  5. anonymous

    anonymous Guest

     
  6. anonymous

    anonymous Guest

    Because Sanofi leadership being hijacked by dipstick narcissist manager V.C in the central region. Micromanager who wants to control everything. She does not shut up and listen to tenured reps or the good mgrs. You can’t talk candidly around her bc she scares everybody with compliance threats so no one challenges her. She can’t read the numbers and has flawed assumptions. If you take her voice away, things will improve. Can’t tell you how many departures are the direct result of her meddling.
     
  7. anonymous

    anonymous Guest

    Has nothing to do with the fact that the Sanofi Regeneron relationship within every BU is dysfunctional, specifically at the top. Oncology doesn’t make you special and immune to the dysfunction
     
  8. anonymous

    anonymous Guest

    The need to ax region business directors first. They are useless.
     
  9. anonymous

    anonymous Guest

    Some do need to go - however CD is great and brings a ton to the team.
     
  10. anonymous

    anonymous Guest

    From the brilliant minds that brought the oncology world ZalCRAP.
     
  11. anonymous

    anonymous Guest

    Yes CD is great! I agree. But he’s stuck shred decision making with dipstick V.C. CD needs to go with his own instincts and tell her to go away. She is ruining the entire center of the country
     
  12. anonymous

    anonymous Guest

    As long as we don’t have a downsizing I’ll do what I’m told since I just started here in the last few months. We need to be thankful we still have a job during this terrible time for our country.
     
  13. anonymous

    anonymous Guest

    How’s the libtato going during the pandemic friends?

    Getting lots of new patient starts tomorrow these days?
     
  14. anonymous

    anonymous Guest

    Any breakthrough Metoomuvab data at ASCO?
     
  15. anonymous

    anonymous Guest

    DOA
     
  16. anonymous

    anonymous Guest

    We dislike working with 25% of your sales force. We smile to your face and pretend the collaboration is positive.
     
  17. anonymous

    anonymous Guest

    Pharma at it's best. This is no different than most JV's between companies. Get over it. You are highly compensated for a easy job.
     
  18. anonymous

    anonymous Guest

    Pembro FDA-approved. The fat lady is walking onto the stage.
     
  19. anonymous

    anonymous Guest

    Pembro - q6w dosing. It’s over.
     
  20. anonymous

    anonymous Guest

    How many of those 70 year olds are coming in for their meetoomovab infusions these days?